HomeNews

News

  • Allergan’s Ubrogepant registers second Positive Ph 3 Trial results in Migraine

    • April 28, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Schizophrenia drug ALKS 3831 completes Patient enrollment in a pivotal study

    • April 27, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • New data demonstrates Eptinezumab Increased Migraine-Free Intervals and improved Quality-of-Life Outcomes in Episodic Migraine patients

    • April 27, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • FDA re-examining safety of Nuplazid post reports of spike in adverse event

    • April 27, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Phase 2 Clinical Trial of GRF6019 in Alzheimer’s Disease initiated by Alkahest

    • April 26, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Galcanezumab reduces Migraine days for patients failing on other therapies, highlights new subgroup analysis

    • April 26, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Ph 2 results of Ublituximab (TG-1101) in MS patients announced by TG Therapeutics at AAN 2018

    • April 26, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Ph 2b trial results of MN-166 (ibudilast) in Progressive MS presented at AAN 2018

    • April 26, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Trelegy Ellipta gains expanded indication in the US for the treatment of patients with COPD

    • April 25, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • New Epilepsy research to find Biomarkers for Treatment of Focal Seizures in patients

    • April 25, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more